Massachusetts-based Luminopia landed an FDA De Novo for its virtual reality digital therapeutic focused on helping children improve amblyopia, commonly called lazy eye.
The therapy, called Luminopia One, is geared toward children living with the condition between the ages of 4 and 7 and is focused on improving their visual acuity. Children put on a VR headset and are then shown “therapeutically...
